More about

Cedars Sinai

News
May 17, 2018
5 min read
Save

Bicuspid Aortic Valves Present Challenges for TAVR

Bicuspid Aortic Valves Present Challenges for TAVR

Is TAVR appropriate for patients with bicuspid valves?

News
February 01, 2018
1 min read
Save

Online decision tool helps IBD patients choose biologic therapy

Online decision tool helps IBD patients choose biologic therapy

Researchers have developed a new online tool designed to help patients with inflammatory bowel disease navigate different options for biologic therapy and decide which one would work best for them, according to a study published in the American Journal of Gastroenterology’s “Putting Patients First” special issue.

News
October 04, 2017
4 min read
Save

Sherman Prize winner discusses integration, cooperation in IBD

Sherman Prize winner discusses integration, cooperation in IBD

In his long career as a gastroenterologist, Stephen R. Targan, MD, has seen many innovations and treatments emerge in his field.  But, throughout these changes over 30 years, one guiding principle has remained the same.

News
September 13, 2017
12 min read
Save

Debate: Benefits, harms of social media sharing from medical conferences

Debate: Benefits, harms of social media sharing from medical conferences

The number of tweets that came out of the American Society of Breast Surgeons Annual Meeting between 2013 and 2016 increased by 600%, according to results published in the Annals of Surgical Oncology.

News
July 21, 2017
1 min read
Save

Sherman Prize honors researchers for their work in Crohn’s, UC

The Bruce and Cynthia Sherman Charitable Foundation has announced the 2017 recipients of the Sherman Prize for their research in the treatment of Crohn’s disease and ulcerative colitis.

News
June 12, 2017
2 min read
Save

IBD patients with certain clinical, serological, genetic markers more likely to respond poorly to anti-TNFs

IBD patients with certain clinical, serological, genetic markers more likely to respond poorly to anti-TNFs

Primary nonresponse to anti-TNF therapy was more likely in patients with inflammatory bowel disease with certain colonic phenotypes, according to new research. These predictors could be used to help personalize IBD management.

News
June 02, 2017
2 min read
Save

Aldoxorubicin improves PFS in patients with relapsed soft tissue sarcoma

CHICAGO — Aldoxorubicin monotherapy appeared well tolerated and may improve outcomes compared with standard treatments for relapsed/refractory soft tissue sarcoma, according to results of a phase 3 clinical trial presented at the ASCO Annual Meeting.

News
May 26, 2017
3 min watch
Save

VIDEO: Expert discusses breath testing, microbiome link in IBS

VIDEO: Expert discusses breath testing, microbiome link in IBS

CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai Medical Center in Los Angeles, discusses new developments in understanding the relationship between irritable bowel syndrome and the gut microbiome, and specifically developments in breath testing and emerging microbiome therapeutics shared at the meeting.

News
May 23, 2017
2 min read
Save

IBD patients on social media focus on risks rather than benefits of biologics

IBD patients on social media focus on risks rather than benefits of biologics

A study of social media posts showed patients with inflammatory bowel disease more often share their concerns about the negative side effects of biologics rather than their benefits or costs, leading investigators to conclude that physicians should do more to help patients understand their treatment options.

News
May 12, 2017
2 min watch
Save

VIDEO: Older age, more severe IBS linked to relapse after treatment with Xifaxan

VIDEO: Older age, more severe IBS linked to relapse after treatment with Xifaxan

CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai, discusses his research on predicting response to Xifaxan in patients with irritable bowel syndrome.

View more